Serving To Educate Primary Care Clinicians On Metabolic Issues
Home
Subscribe
Feedback
Contact Us
Evidence Based Medicine
Medical Education
Metabolic Diseases
About Us
PCMG CME
PCMG Non-CME
Resources
Needs Survey
Commentaries
Survey
Webinar Menopause
The following patients all present with complaints of menopause-related VMS. For which patient would you recommend pharmacologic treatment with hormone therapy?
[ Required ]
A 62-year-old woman who has moderate VMS and says that she is afraid of getting a blood clot from taking hormones.
A 69-year-old woman who has a recurrence of VMS; when she took estrogen in the past, it was the only thing that helped with her symptoms. She has hypertension, hyperlipidemia, and diabetes.
A 51-year-old woman with a history of breast cancer, taking tamoxifen. She fears weight gain and sexual side effects from drugs but wants to try something for VMS.
A 54-year-old woman with severe menopausal VMS, hypothyroidism, and no history of cancer or thromboembolism.
Which statement is correct about novel neurokinin 3 receptor (NK3R) antagonists for treatment of menopause-associated VMS?
[ Required ]
In late-stage clinical trials, NK3R antagonists have demonstrated superiority over hormone therapy for reduction in VMS frequency and severity.
NK3R antagonists are thought to reduce VMS by altering stimulation of neurons in the hypothalamic thermoregulatory center
NK3R antagonists are contraindicated in women who have severe VMS
There are currently 3 FDA-approved NK3R antagonists available in the United States
How confident do you feel in your answer to the previous question?
[ Required ]
Select...
Very confident
Confident
Somewhat confident
Not confident
Submit